Tag: Medtronic

top 10

Vascular News’ top 10 most popular stories of January 2024

January's top 10 highlights new guidelines from the European Society for Vascular Surgery (ESVS), an expert consensus roundtable on the benefits of intravascular ultrasound...

Simona Zannetti returns to Medtronic to lead aortic business

Medtronic recently announced that Simona Zannetti has been appointed as the general manager of its aortic business.  Zannetti previously spent 21 years at Medtronic. She...
biopact

Two-year BIOPACT randomised controlled trial analysis demonstrates “persistent excellence” for low-profile...

Biotronik has announced the presentation of two-year results from the investigator-initiated BIOPACT randomised controlled trial (RCT) by principal investigator Koen Deloose (AZ Sint-Blasius Hospital,...
TRANSCEND

TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of...

Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics' TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18...
Cydar Medical

First patient treated in global strategic collaboration between Cydar Medical and...

Cydar Medical has announced the successful treatment of the first patient in a strategic collaboration with Medtronic. The collaboration, which spans 40 sites across...

Amazon executive joins Medtronic to spearhead development in robotics and implantables

Medtronic has announced that Ken Washington has been appointed chief technology and innovation officer. Washington joins Medtronic from Amazon where he served as vice president...
Endurant

Endurant stent graft proves efficacious and durable in ENGAGE 10-year data

A first-to-podium presentation at the 2023 Charing Cross (CX) International Symposium (25–27 April, London, UK) saw Hence Verhagen (Erasmus Medical Center, Rotterdam, The Netherlands)...

BIOPACT RCT suggests Passeo-18 Lux DCB non-inferior to IN.PACT Admiral DCB

 Koen Deloose (Dendermonde, Belgium) talks to Vascular News about the key one-year data from the BIOPACT randomised controlled non-inferiority trial, which evaluated the safety...
top 10

Vascular News’ top 10 most popular stories of January 2023

January's top 10 highlights an individual patient data meta-analysis on the safety of carotid endarterectomy in the elderly and a new randomised trial on...

Roundtable: Will latest IN.PACT AV Access data impact practice and can...

NOTE: This video is ONLY available to watch in selected countries and geographies  In this Vascular News roundtable, Andrew Holden (moderator; Auckland, New Zealand) is joined...
HawkOne atherectomy

Medtronic announces first enrolment in head-to-head global randomised trial evaluating durability...

Medtronic has announced the first patient enrolment in the ADVANCE trial, a head-to-head randomised controlled trial of two leading aortic stent graft systems, the...

SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other...

Medtronic has announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The late-breaking data were presented at the...
SurVeil

SurVeil DCB demonstrates sustained durability of safety, efficacy endpoints in TRANSCEND

In the TRANSCEND clinical trial, the SurVeil drug-coated balloon (DCB; Surmodics) demonstrated "excellent efficacy and safety" out to 24-month follow-up. This is according to...

ABRE clinical study 36-month data show sustained effectiveness of Abre venous...

Medtronic has announced the 36-month final results from the ABRE clinical study. The purpose of the ABRE clinical study was to evaluate the safety...
top 10

Vascular News’ top 10 most popular stories of September 2022

September's top 10 highlights a randomised trial that aims to examine early endovascular aneurysm repair (EVAR) in women, new radiation safety guidelines from the...

Medtronic receives CE mark for the first balloon-expandable covered stent indicated...

Medtronic announced that it has recently received CE mark for its Radiant balloon-expandable covered stent, the first and currently, only, covered stent indicated for...
endoAVF

Vascular access creation: EndoAVF keeps future options open, but is not...

Based on over four years of experience in a single centre, Robert Shahverdyan (Asklepios Klinik Barmbek, Hamburg, Germany) claims that endovascular arteriovenous fistula (endoAVF)...

Medtronic gains FDA approval for IN.PACT 018 DCB

Medtronic has announced approval from the US Food and Drug Administration (FDA) for the IN.PACT 018 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, a...
EuroPCR

EuroPCR 2022: Studies underscore potential of renal denervation as an adjunctive...

Late-breaking trial data presented at EuroPCR 2022 (17–20 May, Paris, France) underscore the potential of renal denervation as an adjunctive therapy to treat hypertension,...

First time data release: View the full IN.PACT AV Access trial...

NOTE: This video is ONLY available to watch in selected countries and geographies In a late-breaking Podium 1st presentation at the 2022 Charing Cross...

IN.PACT AV Access: Three-year data support use of paclitaxel-coated balloon as...

The 36-month results from the IN.PACT AV Access study (Medtronic)—which were presented for the first time during at the 2022 Charing Cross (CX) International...

Medtronic names Laura Mauri as new chief scientific, medical and regulatory...

Medtronic has announced that Laura Mauri has been appointed as the company’s chief scientific, medical and regulatory officer. This appointment adds to Mauri's prior responsibilities...

Cydar Medical announces strategic collaboration with Medtronic

Cydar Medical recently announced it has entered a strategic collaboration with Medtronic. Under the pilot arrangement, Cydar’s EV Maps software will be introduced to...
top 10

Vascular News’ top 10 most popular stories of March 2022

A review of intraoperative adverse events in patients treated with fenestrated and branched endovascular aneurysm repair, meta-analysis findings on peripheral arterial disease symptoms in...
AV access

Medtronic issues voluntary recall for subset of IN.PACT Admiral and IN.PACT...

Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheters due to the potential...
top 10

Vascular News’ top 10 most popular stories of January 2022

Breakthrough designation for a new drug-eluting stent from Cook Medical, a meta-analysis on the safety of expedited carotid artery surgery vs. expedited stenting after...
HawkOne atherectomy

Medtronic recalls HawkOne directional atherectomy system due to risk of tip...

According to the US Food and Drug Administration (FDA), Medtronic is recalling its HawkOne directional atherectomy system. The FDA has identified the recall as a...
AV access

IN.PACT Admiral DCB performs well across wide range of clinical and...

In a pooled analysis of the predictors of drug-coated balloon (DCB) effectiveness, the IN.PACT Admiral DCB (Medtronic) performed well across a broad range of...
ellipsys five-year data

Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data

The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (pAVFs) for haemodialysis—with new, long-term...

Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study

Medtronic today announced findings from a new study of patient preferences for the treatment of hypertension. The findings are set to be presented during...

VIVA 2021: IN.PACT Admiral DCB found to provide “high five-year freedom...

Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically-driven target lesion revascularisation (TLR) among prespecified chronic total occlusion (CTO),...
top 10

Vascular News’ top 10 most popular stories of September 2021

September's top 10 features five-year ACST-2 results, a new tool to assess amputation risk following popliteal vascular injury, and an interview highlighting the questions...
HawkOne atherectomy

Medtronic receives CE mark approval for radial artery access portfolio

Medtronic today announced it has received CE mark approval for its radial artery access portfolio, which includes the Rist radial access selective catheter and the Rist...
Biotronik

BIOPACT head-to-head non-inferiority randomised controlled trial completes enrolment

Biotronik is proud to announce the completion of enrolment of the investigator-initiated BIOPACT randomised controlled trial (RCT). This non-inferiority study evaluates the safety and...

Medtronic receives CE mark for 200mm and 250mm IN.PACT Admiral DCBs

Medtronic has announced CE mark approval and the European launch of the 200mm and 250mm IN.PACT Admiral drug-coated balloons (DCBs). The product is intended...
trerotola misra tan av access dcbs drug coated balloons

More mixed results for DCBs in AV access maintenance as evidence...

Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...

Medtronic provides updated patient management recommendations regarding Valiant Navion recall

This week Medtronic announced that it has sent physicians updated patient management recommendations related to its voluntary recall of the Valiant Navion thoracic stent...

EuroPCR 2021: Late-breaking data demonstrate long-term benefits of Medtronic radiofrequency renal...

Medtronic today announced new clinical data from the Global SYMPLICITY registry (GSR) indicating that renal denervation with the Medtronic Symplicity renal denervation system was...
Medtronic IN.PACT AV

Two-year IN.PACT AV Access results presented at CX 2021

Medtronic recently announced the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study. The data, which were presented virtually...
top 10

Vascular News’ top 10 most popular stories of March 2021

Newly-published data on the benefits of a dedicated vascular limb salvage clinic, key product launches in the vascular access space, and evidence to suggest...

Medtronic launches Chameleon PTA balloon catheter in selected countries

Medtronic recently announced the launch of its Chameleon percutaneous transluminal angioplasty (PTA) balloon catheter in the following countries: Germany, Italy, Portugal, South Africa, Spain,...
Medtronic IN.PACT AV

Medtronic launches IN.PACT AV DCB in Japan for patients undergoing haemodialysis

Medtronic has announced the launch of IN.PACT AV drug-coated balloon (DCB) in Japan. IN.PACT AV DCB is indicated for the treatment of obstructive lesions...

Medtronic announces voluntary recall of unused Valiant Navion thoracic stent graft...

Medtronic has voluntarily issued a global recall of its Valiant Navion thoracic stent graft system and informed physicians to immediately cease use of the...

ChEVAR technique essentials: A practical guide to chimney endovascular aneurysm repair

NOTE: This supplement is only available to read in selected countries and geographies In this supplement, sponsored by Medtronic: From a bailout procedure to a...

DCB in dialysis access: Do we finally have the right evidence?

NOTE: This supplement is only available to read in selected countries and geographies In this supplement, sponsored by Medtronic: Tobias Steinke outlines his treatment algorithm...

Sac regression with Endurant is associated with decreased risk of all-cause...

"Sac regression should be the new paradigm of success after EVAR ," concluded Dittmar Böckler (University of Heidelberg, Heidelberg, Germany) at the European Society...
Medtronic

Medtronic to acquire Avenu Medical

Medtronic today announced the planned acquisition of Avenu Medical, a medical device company focused on the endovascular creation of arteriovenous (AV) fistulae for patients...

Medtronic begins real-world, post-market study of Valiant Navion in patients with...

Medtronic today announced the start of a prospective, observational, global, multicentre, real-world, post-market study to evaluate the safety and effectiveness of the Valiant Navion...

Global SYMPLICITY Registry shows renal denervation lowered blood pressure in patients...

Medtronic has reported new data from the Global SYMPLICITY Registry (GSR), which showed that renal denervation (RDN) with the Medtronic Symplicity renal denervation system...
tack

TOBA III clinical trial results published in the Journal of Vascular...

Intact Vascular has announced the peer-reviewed publication of its Tack optimised balloon angioplasty (TOBA) III 12-month clinical trial results in the Journal of Vascular Surgery. The multi-centre, single-arm,...

Expanding treatment possibilities in TEVAR

NOTE: This supplement is only available to read in selected countries and geographies In this supplement, sponsored by Medtronic: Fabio Verzini discusses his clinical experience...
Ramon Varcoe

“Excellent” long-term results after EVAR using Endurant stent graft in 180...

Results from a real-world experience over more than 10 years using the Endurant stent graft (Medtronic) demonstrate that it is safe and effective, with...
Medtronic

Medtronic provides ventilator progress update

Medtronic has announced updates regarding its efforts to increase ventilator production around the globe. The company is announcing progress in the ramp-up of its...
Medtronic

Medtronic shares ventilation design specifications to accelerate efforts to increase global...

Medtronic has announced it is publicly sharing the design specifications for the Puritan Bennett 560 (PB 560) to enable participants across industries to evaluate...

LINC 2020: Real-world evidence shows no increased mortality signal with paclitaxel-coated...

 Dierk Scheinert (Leipzig, Germany) moderates a panel with Eva Freisinger (Münster, Germany) and Thomas Zeller (Bad Krozingen, Germany) to discuss the developments over the...

COMPARE RCT shows similar key outcomes between low- and high-dose drug-coated...

The first head-to-head randomised controlled trial to directly compare two different drug-coated balloons—the lower-dose density (2μg/mm2) Ranger and higher-dose density (3.5μg/mm2) IN.PACT—showed similar results...

Medtronic IN.PACT™ AV DCB, now approved for AV fistula maintenance in...

 Watch Andrew Holden (Auckland, New Zealand) present the six-month results of the IN.PACT AV Access trial. The multicentre, prospective, randomised controlled trial shows that treatment...

Medtronic presents one-year Valiant Navion, four-year ANCHOR registry clinical outcomes

Medtronic has announced one-year outcomes for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR) and four-year clinical outcomes from the ANCHOR...
Medtronic IN.PACT AV

Medtronic DCB receives US FDA approval to treat arteriovenous fistula lesions

Medtronic today announced US Food and Drug Administration (FDA) approval of the IN.PACT AV drug-coated balloon (DCB), a paclitaxel-coated balloon indicated for the treatment...

Medtronic announces Shonin approval and launch of the Valiant Navion thoracic...

Medtronic today announced Shonin approval from the Ministry of Health, Labour and Welfare (MHLW) and the launch of the Valiant Navion thoracic stent graft...

BIBA Briefings: Medtronic receives US FDA Breakthrough Device Designation for complex...

The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Medtronic for its novel Valiant thoracoabdominal aneurysm (TAAA) stent graft. A...

Medtronic receives FDA breakthrough device designation for its Valiant Navion LSA...

Medtronic today announced it has received breakthrough device designation from the US Food and Drug Administration (FDA) for its Valiant TAAA stent graft system...

Omar Ishrak to step down as Medtronic CEO next year

Omar Ishrak, Medtronic’s chairman and CEO is to retire on 26 April 2020, following the end of the company’s current fiscal year. Also, the...

Omar Ishrak to step down as Medtronic CEO next year

Omar Ishrak, Medtronic’s chairman and CEO is to retire on 26 April 2020, following the end of the company’s current fiscal year. Also, the...
AV access

CIRSE 2019: IN.PACT AV access trial meets primary safety and effectiveness...

Medtronic has announced the first-ever results from the IN.PACT AV access clinical study comparing the investigational IN.PACT AV drug-coated balloon (DCB) to percutaneous transluminal...
Medtronic

Medtronic statement regarding updated FDA letter to healthcare providers on paclitaxel...

Medtronic has issued the following statement regarding the US Food and Drug Administration’s (FDA) updated letter to healthcare providers for paclitaxel-devices in patients with...

BIOPACT-RCT set to compare Passeo-18 Lux and IN.PACT Admiral DCBs in...

iD3 Medical has announced that it has received approval in Belgium to initiate a randomised controlled trial, BIOPACT-RCT: a physician-initiated multicentre trial evaluating the...

CX 2019: Evidence supports safety of paclitaxel-coated devices

 At the Charing Cross International Symposium, Gary Ansel (Columbus, Ohio) moderates a global panel that includes Thomas Albrecht (Berlin, Germany), Peter Schneider (San Francisco,...

Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Medtronic has issued the following statement regarding revised clinical study data: On 15 February, 2019, Medtronic issued a statement regarding a programming error in the...
Medtronic

Medtronic revises IN.PACT post-market study data due to programming error, but...

Medtronic has issued the following statement regarding revised clinical study data: Recently, Medtronic became aware of a programming error in the clinical data reporting isolated...

Patient-level analysis shows no correlation between paclitaxel and mortality—reactions from LINC

 Renowned experts expressed confidence in the continued use of paclitaxel-coated devices after independent patient-level data presented at LINC 2019 did not show correlation between...
Japanese

IN.PACT Admiral DCB three-year results reveal “consistent and durable” treatment

The IN.PACT Admiral drug-coated balloon (DCB; Medtronic) exhibits a consistent and durable treatment effect in “a more complex patient demographic than typically seen in...
medtronic

Medtronic and Boston Scientific stand by paclitaxel devices despite Katsanos’ critical...

Speaking to investors at the JP Morgan healthcare conference in San Francisco, executives from Medtronic and Boston Scientific said their data do not show...

FDA approves Valiant NAVION for inclusion in physician-sponsored IDE

The Valiant NAVION stent graft system (Medtronic) has been approved by the US Food and Drug Administration (FDA) for inclusion in a physician-sponsored investigational...

Outcomes of the ANCHOR registry show consistent outcomes for endoanchors at...

Real-world outcomes in patients from the ANCHOR registry at three years show safe and effective performance of the Heli-FX EndoAnchor system (Medtronic) in complex...

Valiant Navion receives CE mark approval

CE mark approval has been granted for the Valiant Navion thoracic stent graft system (Medtronic) for the minimally invasive repair of all lesions of...

US FDA approve new study of Medtronic’s Spyral renal denervation system

The FDA have given Medtronic approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system in patients with hypertension who...

IN.PACT SFA Trial five-year data and Total IN.PACT All-Subjects analysis presented...

  The five-year and final results from the pivotal IN.PACT SFA Trial and one-year all-subjects results from the Total IN.PACT Pooled Analysis of the IN.PACT...

Valiant Navion thoracic stent graft receives FDA approval

The US Food and Drug Administration (FDA) has approved Valiant Navion thoracic stent graft system (Medtronic) for the minimally invasive repair of all lesions...

IN.PACT Admiral DCB launched in Japan

Medtronic plc has announced the full commercial launch of the IN.PACT Admiral drug-coated balloon (DCB) in Japan. The launch follows the completion of a...
IN.PACT

IN.PACT Admiral DCB receives FDA approval for long SFA lesions

Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) to treat long superficial...

IN.PACT SFA Japan trial shows significantly higher patency compared with PTA...

New two-year results from the IN.PACT SFA Japan trial were presented at the Leipzig Interventional Course (LINC; 30 January–2 February, Leipzig, Germany) by Osamu...

How would you treat these lesions?

This educational supplement is for distribution within Europe only. In this supplement: The rationale of directional atherectomy and DCB angioplasty for the treatment of “no-stent zones” CASE #1:...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...

ENCHANT will evaluate ChEVAR technique with Endurant II/IIs stent graft system

The post-market, non-interventional, multicentre, non-randomised, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety...

Medtronic launches ChEVAR parallel graft technique study using Endurant II/IIs

Medtronic has announced the launch of the ENCHANT (Endurant ChEVAR New Indication Trial) study. The post-market, non-interventional, multi-centre, non-randomised, single-arm study will enrol approximately...

Endurant II/IIs stent graft receives FDA approval for short neck anatomies...

  Medtronic has received US Food and Drug Administration (FDA) approval for the Endurant II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients...

From SYMPLICITY HTN-1 to SPYRAL HTN-OFF MED: The story of renal...

It is now almost a decade since the first patient underwent catheter-based renal denervation as a participant in a safety and proof-of concept study...

Medtronic launches Concerto 3D detachable coil system in USA and Europe

Medtronic is expanding its embolisation product portfolio with the launch of the Concerto 3D detachable coil system. The system was launched at the Cardiovascular...

Five-year ENGAGE data demonstrate comparable EVAR outcomes in male and female...

Five-year data from Medtronic’s ENGAGE global registry indicate that endovascular aneurysm repair (EVAR) outcomes are comparable between male and female patients when using the...

Two- and four-year IN.PACT Admiral drug-coated balloon data indicate good mid-...

Medtronic has released data reinforcing the durability and safety of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD). The...

First patient enrolled in study of Medtronic IN.PACT arteriovenous access drug-coated...

The first patient has been enrolled in Medtronic’s IN.PACT arteriovenous (AV) access drug-coated balloon (DCB) study for use in patients with end-stage renal disease. The...

QT Vascular enters into asset purchase option agreement with Medtronic

QT Vascular has entered into an asset purchase option agreement with Medtronic for the acquisition of the group's non-drug coated Chocolate percutaneous transluminal angioplasty...

Five-year Medtronic ENGAGE Registry data show positive real-world outcomes for Endurant...

Medtronic has reported that its Endurant II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a...
IN.PACT

Consistent results for Medtronic IN.PACT Admiral in complex peripheral artery disease...

Two new sub-analyses from the IN.PACT Global Study of the IN.PACT Admiral in patients with peripheral artery disease have been reported at the annual...

Leaving nothing behind: Is it time to move away from primary...

This educational supplement is only available in countries in Europe. This educational supplement explores the concept of “leaving nothing behind" in the treatment of the superficial...
IN.PACT

Medtronic launches European below-the-knee clinical study of drug-coated balloon

Medtronic has launched the IN.PACT BTK study to evaluate the effectiveness of using a drug-coated balloon in patients with below-the-knee (BTK) peripheral artery disease. This...

Global cohorts report drug-coated balloon success above the knee and “promising”...

Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...

Promising 12- and 24-month East Asian experiences for drug-coated balloons

Results from two Asian studies presented at LINC 2017 (24–27 January, Leipzig, Germany), show encouraging outcomes for drug-coated balloon versus percutaneous transluminal angioplasty treatment...

Medtronic announces Health Canada licence for IN.PACT Admiral drug-coated balloon

Medtronic Canada, a subsidiary of Medtronic, has announced it has obtained Health Canada licence for the IN.PACT Admiral drug-coated balloon. IN.PACT Admiral is a primary...
IN.PACT

Japanese IN.PACT SFA study demonstrates clinical outcomes consistent with other trials

The one-year clinical outcomes from the MDT-2113 IN.PACT SFA Japan trial have been released. The data was recently presented by Osamu Iida, Kansai Rosai...

Medtronic to distribute QT Vascular’s Chocolate balloon worldwide

QT Vascular has signed a definitive agreement with Medtronic, for the worldwide distribution of its Chocolate percutaneous transluminal angioplasty (PTA) catheter for a period...
IN.PACT

US FDA grants Medtronic investigational device exemption for IN.PACT Admiral AV...

Medtronic has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a study of the IN.PACT Admiral...
IN.PACT

Results from Asia and Belgium demonstrate consistent results from Medtronic IN.PACT...

New data presented at the 2017 Leipzig Interventional Course (LINC) have demonstrated strong efficacy and consistent outcomes for Medtronic’s IN.PACT Admiral drug-coated balloon across...

VeClose trial indicates 24-month non-inferiority of VenaSeal versus radiofrequency ablation

Two-year outcomes of the VeClose pivotal trial have been reported, showing a 94.3% closure rate and “continued non-inferiority results to radiofrequency ablation” when using...

Medtronic receives CE mark for lower-profile HawkOne directional atherectomy system

Medtronic has been granted CE mark approval for the HawkOne directional atherectomy system in a lower profile size for treating patients with peripheral artery...

Scott Hutton appointed general manager of Vascular Intervention at Spectranetics

Scott Hutton has been named general manager of Vascular Intervention at Spectranetics. In this role, Hutton will report directly to the president and chief executive...

Medtronic Endurant II/IIs granted CE mark for ChEVAR parallel graft technique

Medtronic has received CE mark for its Endurant II/IIs stent graft system to treat abdominal aortic aneurysm patients using a ChEVAR procedure—a parallel graft...

VEITH 2016: New data support strength and durability of Endurant II/IIs...

Medtronic announced data supporting the strength and durability of the Endurant II/IIs stent graft system to treat abdominal aortic aneurysm patients. The results, presented...

Valiant Captivia stent graft shows 90% freedom from dissection-related mortality at...

The Valiant Captivia thoracic stent graft system (Medtronic) has demonstrated freedom from all-cause mortality of 79.4% and freedom from dissection-related mortality of 90% at...

Medtronic receives FDA clearance of TrailBlazer angled peripheral support catheter

The US Food and Drug Administration (FDA) has cleared Medtronic’s TrailBlazer angled support catheter for use in the peripheral vascular system. The TrailBlazer angled support...

Medtronic Valiant Captivia demonstrates safety and efficacy at three years

Medtronic has announced new data, demonstrating safety and efficacy at three years in acute complicated type B aortic dissection patients treated with the Valiant Captivia thoracic...
IN.PACT

New data demonstate durability, safety and efficacy for Medtronic’s In.Pact Admiral...

New data, presented in a series of late-breaking clinical trial presentations at the Vascular Interventional Advances (VIVA) 2016 conference in Las Vegas, USA, have...
IN.PACT

US FDA approves first drug-coated balloon for treatment of in-stent restenosis

The US Food and Drug Administration (FDA) has approved Medtronic’s IN.PACT Admiral drug-coated balloon as a treatment for in-stent restenosis in patients with peripheral...

WAVES trial shows 100% vein closure at one month with short...

A post-market evaluation of the VenaSeal closure system (Medtronic) has found that, at one month, 100% of treated veins remained closed, quality of life...

REALITY trial enrols first patient in study evaluating Medtronic directional atherectomy...

Medtronic and VIVA Physicians reported on 27 July 2016 the first patient enrolled in the REALITY Study. The VIVA-sponsored study is assessing outcomes for...
IN.PACT

Medtronic receives FDA approval for IN.PACT Admiral DCB 150mm lengths

Medtronic has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) in longer, 150mm lengths. The 150mm length...